Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3460809rdf:typepubmed:Citationlld:pubmed
pubmed-article:3460809lifeskim:mentionsumls-concept:C1704689lld:lifeskim
pubmed-article:3460809lifeskim:mentionsumls-concept:C0025918lld:lifeskim
pubmed-article:3460809lifeskim:mentionsumls-concept:C0812281lld:lifeskim
pubmed-article:3460809lifeskim:mentionsumls-concept:C0029463lld:lifeskim
pubmed-article:3460809lifeskim:mentionsumls-concept:C0022702lld:lifeskim
pubmed-article:3460809lifeskim:mentionsumls-concept:C0743223lld:lifeskim
pubmed-article:3460809lifeskim:mentionsumls-concept:C0085752lld:lifeskim
pubmed-article:3460809lifeskim:mentionsumls-concept:C0050885lld:lifeskim
pubmed-article:3460809pubmed:issue4lld:pubmed
pubmed-article:3460809pubmed:dateCreated1986-9-17lld:pubmed
pubmed-article:3460809pubmed:abstractTextDisposition kinetics of Adriamycin (ADR), adriamycinol (AOL) and their 7-deoxyaglycones (ADR-DONE and AOL-DONE) have been studied in AKR mice bearing a s.c. growing ROS tumour after i.v. administration of 10 mg/kg. ADR and its metabolites were extracted from tissues by two different methods, separated and identified by HPLC. Tissue 7-deoxyaglycones were isolated, purified and then identified by HPLC, TLC and mass spectrometry. Kinetic profiles of ADR showed rapid equilibration of the drug with well perfused tissues but a slower and complex equilibration of the drug with the ROS tumour. Serum and tissue profiles of AOL were similar to the parent drug. From the kinetic profiles of the 7-deoxyaglycones it appeared that in the tissues their formation was rapid, with ADR-DONE always appearing first. Maximum concentrations of ADR-DONE were reached in the liver and heart only 10 min after drug administration. Estimated half lives of ADR-DONE were in liver, 1.1 hr and in heart, 2.8 hr and for AOL-DONE in liver, 5.4 hr, in heart, 5.1 hr and in serum, 4.1 hr.lld:pubmed
pubmed-article:3460809pubmed:languageenglld:pubmed
pubmed-article:3460809pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3460809pubmed:citationSubsetIMlld:pubmed
pubmed-article:3460809pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3460809pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3460809pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3460809pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3460809pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3460809pubmed:statusMEDLINElld:pubmed
pubmed-article:3460809pubmed:monthAprlld:pubmed
pubmed-article:3460809pubmed:issn0277-5379lld:pubmed
pubmed-article:3460809pubmed:authorpubmed-author:WillmottNNlld:pubmed
pubmed-article:3460809pubmed:authorpubmed-author:CummingsJJlld:pubmed
pubmed-article:3460809pubmed:authorpubmed-author:MerrySSlld:pubmed
pubmed-article:3460809pubmed:issnTypePrintlld:pubmed
pubmed-article:3460809pubmed:volume22lld:pubmed
pubmed-article:3460809pubmed:ownerNLMlld:pubmed
pubmed-article:3460809pubmed:authorsCompleteYlld:pubmed
pubmed-article:3460809pubmed:pagination451-60lld:pubmed
pubmed-article:3460809pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3460809pubmed:meshHeadingpubmed-meshheading:3460809-...lld:pubmed
pubmed-article:3460809pubmed:meshHeadingpubmed-meshheading:3460809-...lld:pubmed
pubmed-article:3460809pubmed:meshHeadingpubmed-meshheading:3460809-...lld:pubmed
pubmed-article:3460809pubmed:meshHeadingpubmed-meshheading:3460809-...lld:pubmed
pubmed-article:3460809pubmed:meshHeadingpubmed-meshheading:3460809-...lld:pubmed
pubmed-article:3460809pubmed:meshHeadingpubmed-meshheading:3460809-...lld:pubmed
pubmed-article:3460809pubmed:meshHeadingpubmed-meshheading:3460809-...lld:pubmed
pubmed-article:3460809pubmed:meshHeadingpubmed-meshheading:3460809-...lld:pubmed
pubmed-article:3460809pubmed:meshHeadingpubmed-meshheading:3460809-...lld:pubmed
pubmed-article:3460809pubmed:meshHeadingpubmed-meshheading:3460809-...lld:pubmed
pubmed-article:3460809pubmed:year1986lld:pubmed
pubmed-article:3460809pubmed:articleTitleDisposition kinetics of adriamycin, adriamycinol and their 7-deoxyaglycones in AKR mice bearing a sub-cutaneously growing ridgway osteogenic sarcoma (ROS).lld:pubmed
pubmed-article:3460809pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3460809pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3460809lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3460809lld:pubmed